This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEW YORK, Feb. 8, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 15
th Annual BIO CEO & Investor Conference being held at the Waldorf Astoria Hotel in New York City. Mr. Weiss' presentation is scheduled to take place on Monday, February 11, 2013 at 3:30 PM EST. A live webcast of this presentation will be available on the Events page of the Company's website at
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma and Chronic Lymphocytic Leukemia. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. TG Therapeutics is headquartered in New York City.
The TG Therapeutics logo is available at
TGTX - G
CONTACT: Jenna Bosco
Director - Investor Relations
TG Therapeutics, Inc.